175277-49-3 Usage
Uses
Used in Organic Synthesis:
6-METHOXYPYRIDINE-3-CARBOTHIOAMIDE is used as a building block in organic synthesis for the creation of various pharmaceutical and agrochemical compounds. Its unique structure and functional groups contribute to the development of new molecules with potential applications in these fields.
Used in Pharmaceutical Research:
In pharmaceutical research, 6-METHOXYPYRIDINE-3-CARBOTHIOAMIDE serves as a key intermediate for the synthesis of therapeutic agents. Its presence in the molecular structure can influence the pharmacological properties of the final product, enhancing their efficacy and selectivity.
Used in the Synthesis of Heterocyclic Compounds:
6-METHOXYPYRIDINE-3-CARBOTHIOAMIDE is utilized as a reagent in the synthesis of heterocyclic compounds, which are important in various chemical and pharmaceutical applications due to their diverse chemical and biological properties.
Used as a Ligand in Coordination Chemistry:
6-METHOXYPYRIDINE-3-CARBOTHIOAMIDE also finds application as a ligand in coordination chemistry, where it can form complexes with metal ions. These complexes have potential uses in catalysis, materials science, and as models for biological systems.
Check Digit Verification of cas no
The CAS Registry Mumber 175277-49-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,5,2,7 and 7 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 175277-49:
(8*1)+(7*7)+(6*5)+(5*2)+(4*7)+(3*7)+(2*4)+(1*9)=163
163 % 10 = 3
So 175277-49-3 is a valid CAS Registry Number.
InChI:InChI=1/C7H8N2OS/c1-10-6-3-2-5(4-9-6)7(8)11/h2-4H,1H3,(H2,8,11)
175277-49-3Relevant academic research and scientific papers
C-TERMINAL SRC KINASE INHIBITORS
-
Paragraph 167, (2020/07/14)
Provided herein are novel C-terminal Srk Kinase (CSK) inhibitors, e.g., having Formula G, I, II, or III. Also provided are methods of preparing the novel CSK inhibitors and method of using the novel CSK inhibitors for treating diseases or disorder such as cancer or for promoting immune response in a subject in need thereof. (G)
